eligibility_summary
Adults ≥18 with relapsed/progressed DLBCL/HGBCL (incl. transformed, double-hit, follicular large B-cell), transplant-eligible, ECOG 0–2, PET-avid measurable disease, CD20+, adequate organ function/counts, prior-therapy washout, able to take oral meds, contraception/consent. Exclude: primary/active CNS lymphoma, prior auto-SCT, other active malignancy, prior CD3xCD20 bispecific, uncontrolled infection, HIV, active HBV/HCV, major cardiac, uncontrolled seizures, autoimmune on immunosuppression, recent live vaccine, pregnancy/lactation, drug hypersensitivity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm trial in relapsed/refractory large B‑cell lymphoma tests: 1) Epcoritamab (subcutaneous), a bispecific T‑cell–engaging monoclonal antibody that binds CD3 on T cells and CD20 on B cells to form an immune synapse and drive targeted T‑cell–mediated killing, given with R‑DHAOx salvage, then as post‑ASCT consolidation. 2) R‑DHAOx: Rituximab (anti‑CD20 monoclonal antibody, B‑cell depletion via ADCC/CDC/apoptosis), Dexamethasone (corticosteroid, lympholytic, anti‑inflammatory), Cytarabine (antimetabolite nucleoside analog, inhibits DNA synthesis), Oxaliplatin (platinum DNA crosslinker). Targets/pathways: CD20+ malignant B cells, CD3+ cytotoxic T cells, Fc‑mediated ADCC/CDC, DNA replication and crosslink repair/apoptosis, post‑transplant immune consolidation to clear MRD. Aim: raise pre‑ASCT CR, improve MRD clearance, PFS/EFS, assess safety/deliverability.